NCT03074825View on ClinicalTrials.gov

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

August 15, 2017

Study Completion Date

February 14, 2019

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Chiauranib

Take 50mg orally once daily

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY